CO2021000419A2 - Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos - Google Patents

Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos

Info

Publication number
CO2021000419A2
CO2021000419A2 CONC2021/0000419A CO2021000419A CO2021000419A2 CO 2021000419 A2 CO2021000419 A2 CO 2021000419A2 CO 2021000419 A CO2021000419 A CO 2021000419A CO 2021000419 A2 CO2021000419 A2 CO 2021000419A2
Authority
CO
Colombia
Prior art keywords
isoform
affinity
selective
tgfβ1 inhibitors
tgfβ1
Prior art date
Application number
CONC2021/0000419A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Schurpf
Abhishek Datta
Gregory J Carven
Constance Martin
Alan Buckler
Allan Capili
Kevin B Dagbay
Christopher Chapron
Stefan Wawersik
Christopher Littlefield
Susan Lin
Justin W Jackson
Caitlin Stein
Andrew Avery
Anthony Cooper
Matthew Salotto
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of CO2021000419A2 publication Critical patent/CO2021000419A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18211—Henipavirus, e.g. hendra virus
    • C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2021/0000419A 2018-07-11 2021-01-18 Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos CO2021000419A2 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862696752P 2018-07-11 2018-07-11
US201862718196P 2018-08-13 2018-08-13
US201862737534P 2018-09-27 2018-09-27
US201862758180P 2018-11-09 2018-11-09
US201962810263P 2019-02-25 2019-02-25
US201962827552P 2019-04-01 2019-04-01
PCT/US2019/041373 WO2020014460A1 (en) 2018-07-11 2019-07-11 HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF

Publications (1)

Publication Number Publication Date
CO2021000419A2 true CO2021000419A2 (es) 2021-01-29

Family

ID=67470735

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000419A CO2021000419A2 (es) 2018-07-11 2021-01-18 Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos

Country Status (15)

Country Link
US (2) US12252531B2 (https=)
EP (1) EP3820508A1 (https=)
JP (2) JP7540994B2 (https=)
KR (1) KR102891320B1 (https=)
CN (1) CN112996535B (https=)
AU (1) AU2019302679B2 (https=)
BR (1) BR112021000353A2 (https=)
CL (1) CL2021000073A1 (https=)
CO (1) CO2021000419A2 (https=)
IL (1) IL279914A (https=)
MA (1) MA53125A (https=)
MX (1) MX2021000347A (https=)
PH (1) PH12021550020A1 (https=)
SG (1) SG11202013231SA (https=)
WO (1) WO2020014460A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018068906A2 (pt) 2016-03-16 2019-01-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
CN112512589A (zh) 2018-07-11 2021-03-16 H·李·莫菲特癌症中心研究有限公司 二聚体免疫调节化合物对抗基于cereblon的机制
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
CN113677711B (zh) 2019-01-30 2025-05-30 供石公司 TGFβ的LTBP复合特异性抑制剂及其用途
CN114729370B (zh) 2019-08-28 2025-03-21 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202135862A (zh) 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
CN115485559A (zh) * 2020-03-19 2022-12-16 中外制药株式会社 预测对检查点抑制剂的反应的生物标志物
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
KR20240022608A (ko) * 2021-06-18 2024-02-20 젠자임 코포레이션 항-tgf-베타 항체 제형 및 이의 용도
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
CN113604214B (zh) * 2021-08-09 2023-07-14 青岛大学 一种高稳定性溶瘤肽荧光探针及其制备方法和应用
CN116262137A (zh) * 2021-12-14 2023-06-16 四川大学 一种同时杀伤肿瘤和改善免疫微环境的抗肿瘤联合用药物
CN114236137A (zh) * 2021-12-17 2022-03-25 中山大学·深圳 一种转化生长因子β的体外检测试剂盒及其应用
CN115058440B (zh) * 2022-06-08 2023-08-15 郑州轻工业大学 催化合成天然蔗糖酯的工程菌及其构建方法和应用
TW202434643A (zh) 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
US7803553B2 (en) 2003-09-04 2010-09-28 Riken Methods of use of antibodies which recognize a protease cleavage site of an LAP fragment of TGF-β
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011140285A2 (en) 2010-05-04 2011-11-10 Sirnaomics, Inc. Combinations of tgfbeta and cox-2 inhibitors and methods for their therapeutic application
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
DK2780368T3 (en) 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
JP2016500704A (ja) 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 細胞シグナル伝達を変調するための組成物及び方法
LT2971048T (lt) * 2013-03-11 2019-02-25 Genzyme Corporation Inžineriniu būdu gauti anti-tgf-beta antikūnai ir antigeną surišantys fragmentai
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EA037112B1 (ru) 2015-03-02 2021-02-08 Ригель Фармасьютикалс, Инк. Ингибиторы tgf-
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
WO2017015622A2 (en) 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
AU2017219254B2 (en) 2016-02-17 2019-12-12 Novartis Ag TGFbeta 2 antibodies
CA3055555A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgf.beta.1-binding immunoglobulins and use thereof
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
CN110049773A (zh) 2016-07-14 2019-07-23 供石公司 TGFβ抗体、方法和用途
BR112019013908A2 (pt) 2017-01-06 2020-02-04 Scholar Rock, Inc. inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos
EP3571227A1 (en) 2017-01-20 2019-11-27 Sanofi Anti-tgf-beta antibodies and their use
MA49690A (fr) 2017-07-28 2021-05-19 Scholar Rock Inc Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations
MA53125A (fr) 2018-07-11 2021-05-19 Scholar Rock Inc Inhibiteurs de tgf?1 sélectifs selon l'isoforme à affinité élevée
SI3677278T1 (sl) 2018-07-11 2022-01-31 Scholar Rock, Inc. Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof

Also Published As

Publication number Publication date
CA3105988A1 (en) 2020-01-16
WO2020014460A8 (en) 2020-02-13
CL2021000073A1 (es) 2021-07-30
KR102891320B1 (ko) 2025-11-28
WO2020014460A1 (en) 2020-01-16
PH12021550020A1 (en) 2021-09-13
TW202005981A (zh) 2020-02-01
JP7540994B2 (ja) 2024-08-27
AU2019302679A1 (en) 2021-02-11
MX2021000347A (es) 2021-04-19
CN112996535B (zh) 2026-04-24
US20210122814A1 (en) 2021-04-29
MA53125A (fr) 2021-05-19
KR20210058811A (ko) 2021-05-24
JP2024099673A (ja) 2024-07-25
IL279914A (en) 2021-03-01
JP2021531254A (ja) 2021-11-18
BR112021000353A2 (pt) 2021-08-03
US12252531B2 (en) 2025-03-18
CN112996535A (zh) 2021-06-18
SG11202013231SA (en) 2021-01-28
EP3820508A1 (en) 2021-05-19
US20250257125A1 (en) 2025-08-14
AU2019302679B2 (en) 2026-04-23

Similar Documents

Publication Publication Date Title
CO2021000419A2 (es) Inhibidores de tgfβ1 selectivos de isoforma, de alta afinidad y usos de los mismos
CY1125076T1 (el) Εκλεκτικοι ως προς την ισομορφη tgfb1 αναστολεις και χρησh αυτων
MX2021015024A (es) Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
UY39798A (es) Anticuerpos anti-ccr8 y usos de los mismos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
CO2018010547A2 (es) Receptores quiméricos y métodos de uso de los mismos
PH12020551716A1 (en) Anti-ror antibody constructs
ECSP18005520A (es) Anticuerpos de factor xi y métodos de uso
AR114283A1 (es) Receptores quiméricos de dll3 y métodos para su uso
PH12020550551A1 (en) Anti-cd40 antibody drug conjugates
CR20200483A (es) Anticuerpos anti-hla-g y utilización de los mismos
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CL2020003348A1 (es) Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes
PH12021550096A1 (en) Compositions of fcrn antibodies and methods of use thereof
CL2020003083A1 (es) Inhibidores de masp-2 y métodos de uso
NZ770219A (en) Monoclonal antibodies against human tim-3
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
CL2021002182A1 (es) Formulación de anticuerpos terapéuticos
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
CO2025007355A2 (es) Anticuerpo anti-trem2 y usos del mismo
CL2022001138A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
CO2024007674A2 (es) Anticuerpo anti-trem2 y usos del mismo